Huntington National Bank’s Celldex Therapeutics CLDX Stock Holding History

Huntington National Bank’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.06K	Hold	109	–	–	﹤0.01%	2299
2026 Q1	$3.46K	Hold	109	–	–	﹤0.01%	2156
2025 Q4	$2.96K	Hold	109	–	–	﹤0.01%	2117
2025 Q3	$2.82K	Hold	109	–	–	﹤0.01%	2131
2025 Q2	$2.22K	Buy	+109	New	+$2.12K	﹤0.01%	2191
2016 Q2	–	Sell	-13	Closed	-$6K	–	1527
2016 Q1	$6K	Hold	13	–	–	﹤0.01%	1539
2015 Q4	$3K	Hold	13	–	–	﹤0.01%	1528
2015 Q3	$2K	Hold	13	–	–	﹤0.01%	1626
2015 Q2	$5K	Hold	13	–	–	﹤0.01%	1599
2015 Q1	$6K	Hold	13	–	–	﹤0.01%	1550
2014 Q4	$4K	Buy	+13	New	+$3.23K	﹤0.01%	1562
2014 Q1	–	Sell	-13	Closed	-$5K	–	1237
2013 Q4	$5K	Hold	13	–	–	﹤0.01%	1542
2013 Q3	$7K	Hold	13	–	–	﹤0.01%	1505
2013 Q2	$3K	Buy	+13	New	+$2.56K	﹤0.01%	1593

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Huntington National Bank's CLDX Position: Q2 2026 in Review

Huntington National Bank held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 109 shares worth $4.06K. The position accounts for ﹤0.01% of the portfolio, ranked #2299.

Huntington National Bank first reported a position in CLDX in Q2 2013 and has held it in 14 quarters since. The position peaked at $7K in Q3 2013. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Huntington National Bank held 109 shares of Celldex Therapeutics worth $4.06K as of Q2 2026.
Huntington National Bank left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #2299 holding.
Huntington National Bank first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 14 quarters since.
Huntington National Bank's Celldex Therapeutics position peaked at $7K in Q3 2013.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.